The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
 
Jerome Galon
Employment - HalioDx
Leadership - HalioDx
Stock and Other Ownership Interests - HalioDx
 
John Rossi
No Relationships to Disclose
 
Sarah Turcan
Employment - HalioDx
Leadership - HalioDx
Stock and Other Ownership Interests - HalioDx
 
Corinne Danan
Employment - HalioDx
Leadership - HalioDx
Stock and Other Ownership Interests - HalioDx
 
Frederick Lundry Locke
Consulting or Advisory Role - Cellular Biomedicine Group; Kite, a Gilead company
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - Moffitt (Inst)
 
Sattva Swarup Neelapu
Consulting or Advisory Role - Biovest; Celgene; Medivation; Merck Sharp & Dohme; XEME BioPharma
Speakers' Bureau - Dava Oncology; Dava Oncology
Research Funding - Acerta Pharma; Bristol-Myers Squibb; Celgene; Cellectis; CureTech; Kite, a Gilead company; Merck Sharp & Dohme; Pharmacyclics
Travel, Accommodations, Expenses - Dava Oncology; Dava Oncology
 
David Bernard Miklos
Consulting or Advisory Role - Adaptive Biotechnologies; Genentech; Kite, a Gilead company; Pharmacyclics; Sanofi; Velos
Research Funding - Pharmacyclics
Patents, Royalties, Other Intellectual Property - Pharmacyclics
Travel, Accommodations, Expenses - Pharmacyclics; Sanofi
 
Nancy L. Bartlett
Consulting or Advisory Role - Forty Seven; Kite, a Gilead company (Inst); Seagen
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Immune Design (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Caron Alyce Jacobson
Consulting or Advisory Role - Kite, a Gilead company; Pharmacyclics
 
Ira Braunschweig
Stock and Other Ownership Interests - Kite, a Gilead company
 
Olalekan O. Oluwole
No Relationships to Disclose
 
Tanya Siddiqi
Speakers' Bureau - Janssen; Pharmacyclics; Seagen
 
Yi Lin
Employment - Mayo Clinic
Research Funding - Janssen
 
John Timmerman
No Relationships to Disclose
 
Patrick Michael Reagan
Research Funding - Seagen
 
Lazaros J. Lekakis
No Relationships to Disclose
 
Sherryonne Unabia
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
William Y. Go
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
Jeffrey S. Wiezorek
Employment - Kite, a Gilead company
Leadership - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company
 
Adrian Bot
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite, a Gilead company